Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Sonnet BioTherapeutics Holdings ( (SONN) ) has provided an update.
Sonnet BioTherapeutics has achieved a significant milestone in its Phase 1 SB101 trial for SON-1010, a targeted immunotherapeutic drug, by establishing a maximum tolerated dose of 1200 ng/kg without dose-limiting toxicity. The trial results indicate a promising 48% stability in disease among patients, with one experiencing a notable 45% tumor reduction. These findings highlight the potential of SON-1010 in treating advanced solid tumors, sparking interest for further development and partnerships.
For a thorough assessment of SONN stock, go to TipRanks’ Stock Analysis page.
